English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 23 November 2016, 21:27 HKT/SGT
Share:
    

Source: Jacobson Pharma Corporation Limited
Jacobson Pharma Announces 2016 Interim Results
- Revenue Climbs 11.1% to HK$575.4 Million with;
- Adjusted Profit Up by 30.4% to HK$79.7 Million;
- Declares an Interim Dividend of HK0.8 cents per share

HONG KONG, Nov 23, 2016 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary Chinese medicines and the largest generic drug company in Hong Kong, today announced its unaudited interim results of the Company and its subsidiaries (collectively the "Group") for the six months ended 30 September 2016 (the "Reporting Period").

During the Reporting Period, the Group's revenue increased by 11.1% to HK$575.4 million (1H2015: HK$518.2 million). Gross profit rose by 11.0% to HK$244.6 million (1H2015: HK$220.4 million), with gross profit margin maintained at 42.5%. Profit attributable to the equity shareholders of the Company was HK$57.1 million (1H2015: HK$61.1 million). Excluding the one-off listing expenses of HK$22.6 million, the adjusted profit attributable to the equity shareholders of the Company would have been increased by 30.4% to HK$79.7 million. Basic and diluted earnings per share were HK4.27 cents.

The Group maintains a strong financial position with cash and cash equivalents of HK$699.4 million and net cash at the end of the Reporting Period. The Board has declared a payment of an interim dividend for the six months ended 30 September of HK0.8 cents per share (1H2015: nil).

Business Review

Generic Drugs
During the Reporting Period, revenue of generic drugs achieved HK$506.6 million, representing an increase of 14.0%. Benefitting from the new tenders awarded, the revenue from public sector saw a promising growth of 13.3% to HK$170.7 million, while the revenue from private sector, mainly attributed to the Group's gain in market shares coupled with price escalation across the major selling product categories, increased by 14.4% to HK$335.9 million.

Manufacturing units were operating effectively with a steady rise on production output. There were over 1,100 millions of tablets and capsules, over 1,300 tones of oral liquid and over 94 tones of cream product produced, representing a respective increase of 12%, 28% and 37% versus same period in 2015.

Proprietary Chinese Medicines ("PCM")
During the Reporting Period, the sales of Po Chai Pills in Hong Kong reached HK$36.6 million (1H2015: HK$28.7 million). The total revenue from the PCM segment decreased slightly by 6.9% to HK$68.8 million (1H2015: HK$74.0 million), mainly due to a temporary sales vacuum induced by the cessation of the distribution arrangement with the previous distributor of Puji Pills in China.

Leveraging the high brand awareness of Po Chai Pills and the extensive network and experience of the Group's distribution partners in China, including a subsidiary of Yunnan Baiyao Group Co., Limited and Zhuhai Jinming Medicine Co., Limited, the Group is confident that the sales penetration as well as market shares of Puji Pills in China will be much enhanced along with a full exploitation of its newly secured Over-the-Counter (OTC) classification status.

Product Development
During the Reporting Period, with the addition of 13 newly selected products, there are a total of 98 products in the Group's research and development ("R&D") pipeline. With effective project management protocols, the Group's R&D team has made encouraging progress during this period with the completion of the development process and stability study for 13 products. Furthermore, the Group has finished the formulation development process for another 13 products.

The Group has also achieved good progress on several collaboration projects with local and overseas R&D institutions. The Group has signed a R&D collaboration agreement with the Hong Kong Institute of Biotechnology ("HKIB") on September 23, 2016. The renovation work for the new R&D Center has gone underway, which is targeted to be completed by the end of 2016. The center will be equipped with advanced equipment for development of specialized formulation and coating technology to be applied on premium generics and PCM.

Merger and Acquisition Opportunities
On October 11, 2016, the Group entered into the sale and purchase agreement with an independent third party, pursuant to which the Group agreed to purchase the entire issued share capital of Cawah Holdings Limited and its operating assets which include certain pharmaceutical manufacturing machinery and equipment, at a consideration of HK$100 million.

The transaction was completed on October 31, 2016. The subsidiary of Cawah Holdings Limited namely, Medipharma Limited, is a reputable generic drug manufacturer in Hong Kong, the product portfolio of which is highly complementary to that of the Group. It currently enjoys a decent market share in the public sector and also carries with it some popular and well-known brands such as Doan's Ointment and Methyl Salicylate Compound Ointment thus providing the Group with a platform to explore the potential in the OTC channels. This acquisition helps sustain the Company's leadership position in generic drug market and opens up new business development opportunities in both private and public sectors.

Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma said, "Looking forward, we will leverage our pre-eminent position in Hong Kong to faciliate our business development plans in China, Macau and strategicially-selected markets in Asia Pacific region. We will continue to look for potential targets that either carry products which are complementary to our current portfolio or bear proprietary brands and technologies that would bring about strategic synergies with our current businesses. On the front of product research and development, we will further develop and enhance our portfolio of generic drugs with a focus on specialized formulations. Operationally we also aim to consolidate and streamline our manufacturing capacities as well as to leverage our operational efficiency to ramp up the overall economies of scale and pricing advantage hence maximizing returns to our shareholders."

Contact:
Strategic Financial Relations Limited
Vicky Lee     Tel: (852) 2864 4834  Email: vicky.lee@sprg.com.hk
Angel Li      Tel: (852) 2864 4859  Email: angelok.li@sprg.com.hk
Queenie Chan  Tel: (852) 2864 4851  Email: queenie.chan@sprg.com.hk



Topic: Press release summary
Source: Jacobson Pharma Corporation Limited

Sectors: Daily Finance, Daily News, BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Jacobson Pharma Corporation Limited Releated News
June 29, 2022 23:22 HKT/SGT
雅各臣公布二零二二财年全年业绩
June 29, 2022 23:21 HKT/SGT
雅各臣公佈二零二二財年全年業績
June 29, 2022 23:20 HKT/SGT
Jacobson Pharma Announces FY2022 Annual Results
June 15, 2022 19:58 HKT/SGT
万隆、雅各臣及健倍苗苗成立合资公司 拓展大中华区及亚洲专科药及品牌医疗保健市场
June 15, 2022 19:57 HKT/SGT
萬隆、雅各臣及健倍苗苗成立合資公司 拓展大中華區及亞洲專科藥及品牌醫療保健市場
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575